Home >> Research Area >>Endocrinology and Hormones>>Opioid Receptor>> (±)-U-50488 hydrochloride

(±)-U-50488 hydrochloride

κ-opioid receptor agonist, selective CAS# 67197-96-0

(±)-U-50488 hydrochloride

Catalog No. BCC6665----Order now to get a substantial discount!

Product Name & Size Price Stock
(±)-U-50488 hydrochloride: 5mg $35 In Stock
(±)-U-50488 hydrochloride: 10mg Please Inquire In Stock
(±)-U-50488 hydrochloride: 20mg Please Inquire Please Inquire
(±)-U-50488 hydrochloride: 50mg Please Inquire Please Inquire
(±)-U-50488 hydrochloride: 100mg Please Inquire Please Inquire
(±)-U-50488 hydrochloride: 200mg Please Inquire Please Inquire
(±)-U-50488 hydrochloride: 500mg Please Inquire Please Inquire
(±)-U-50488 hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (±)-U-50488 hydrochloride

Number of papers citing our products

Chemical structure

(±)-U-50488 hydrochloride

3D structure

Chemical Properties of (±)-U-50488 hydrochloride

Cas No. 67197-96-0 SDF Download SDF
PubChem ID 90479733 Appearance Powder
Formula C38H54Cl6N4O2 M.Wt 811.6
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 25 mM in water
Chemical Name 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl]acetamide;2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide;dihydrochloride
SMILES CN(C1CCCCC1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.CN(C1CCCCC1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl.Cl
Standard InChIKey SKWPJQQGGZWRSK-PXOXCKTNSA-N
Standard InChI InChI=1S/2C19H26Cl2N2O.2ClH/c2*1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;;/h2*8-9,12,17-18H,2-7,10-11,13H2,1H3;2*1H/t2*17-,18-;;/m10../s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (±)-U-50488 hydrochloride

DescriptionSelective κ-opioid agonist. At higher concentrations blocks Na+ channels. Separate isomers (+)-U-50488 and (-)-U-50488 also available .

(±)-U-50488 hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(±)-U-50488 hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (±)-U-50488 hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2321 mL 6.1607 mL 12.3213 mL 24.6427 mL 30.8034 mL
5 mM 0.2464 mL 1.2321 mL 2.4643 mL 4.9285 mL 6.1607 mL
10 mM 0.1232 mL 0.6161 mL 1.2321 mL 2.4643 mL 3.0803 mL
50 mM 0.0246 mL 0.1232 mL 0.2464 mL 0.4929 mL 0.6161 mL
100 mM 0.0123 mL 0.0616 mL 0.1232 mL 0.2464 mL 0.308 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on (±)-U-50488 hydrochloride

(±)-U-50488 hydrochloride is a selective agonist for κ-opioid receptor [1].

The κ-opioid receptor (KOR) is a type of opioid receptor for opioid peptide dynorphin and controls addiction. Also, KOR plays an important role in stress, anxiety, anhedonia, depression and increased drug-seeking behavior.

(±)-U-50488 hydrochloride is a selective KOR agonist [1]. In isolated rat DRG neurons, U-50488 (0.3-40 μM) inhibited voltage-independent Ca2+ channel currents. In HeLa cells that didn’t express KOR, U-50488 (20 μM) blocked Ca2+ channels [2].

In rhesus monkeys, U-50488 exhibited potent antinociceptive activity and produced diuresis [1]. U-50488 enhanced contraction of the rabbit vas deferens induced by electrically with IC50 value of 26.5 nM. In mice, U-50488 impaired motor function with ED50 value of 15.3 mg/kg and reduced spontaneous activity [3]. In adult rats, U-50488 increased the threshold required to maintain self-stimulation responding, a depressive-like effect. While, males were significantly more sensitive than females to the threshold-increasing effects [4].

References:
[1].  Tang AH, Collins RJ. Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology (Berl), 1985, 85(3): 309-314.
[2].  Hassan B, Ruiz-Velasco V. The κ-opioid receptor agonist U-50488 blocks Ca2+ channels in a voltage- and G protein-independent manner in sensory neurons. Reg Anesth Pain Med, 2013, 38(1): 21-27.
[3].  Lu SN, Ma SC, Zhang KG, et al. Comparison of pharmacological profile of selective kappa-opioid agonist K-II and U-50488. Yao Xue Xue Bao, 1991, 26(3): 171-174.
[4].  Russell SE, Rachlin AB, Smith KL, et al. Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry, 2014, 76(3): 213-222.

Featured Products
New Products
 

References on (±)-U-50488 hydrochloride

Blockade of the development of morphine tolerance by U-50,488, an AVP antagonist or MK-801 in the rat hippocampal slice.[Pubmed:9517380]

Br J Pharmacol. 1998 Feb;123(4):625-30.

1. In this study, we investigated the effects of different drugs (a kappa-opioid receptor agonist U-50,488, a vasopressin receptor antagonist dPTyr(Me)AVP or an N-methyl-D-aspartate (NMDA) receptor antagonist MK-801) on the development of morphine tolerance in rat hippocampal slices. 2. Hippocampal slices (450 microm) of Sprague-Dawley rats (250-300 g) were used. Slices were continuously superfused with artificial CSF or drugs at 1 ml min(-1). Nichrome wire electrodes were placed in the Schaffer-collateral pathway and used to deliver biphasic 0.2 ms pulses of 5-30 V (0.033 Hz). A glass microelectrode was placed in the CA1 area to record population spikes. 3. When the slices were superfused with 10 microM morphine, the amplitude of population spikes increased 2-3 fold in 30-40 min. However, this effect of morphine decreased, i.e. tolerance developed after continuous superfusion of morphine for 2-6 h. 4. When either U-50,488 (200 nM) or dPTyr(Me) AVP (500 pM) or MK-801 (500 pM) was co-superfused with morphine (10 microM), it significantly blocked the development of morphine tolerance. Nor-BNI (a kappa-opioid receptor antagonist, 200 nM) significantly reversed the inhibitory effect of U-50,488 but not those of dPTyr(Me)AVP or MK-801 on the development of morphine tolerance. 5. These data indicate that kappa-opioid receptors, AVP receptors and NMDA receptors are all involved in the development of morphine tolerance. The suppression of kappa-opioid receptor activity after chronic morphine may occur before the activation of AVP receptors or NMDA receptors during the development of morphine tolerance.

U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs.[Pubmed:8045272]

Eur J Pharmacol. 1994 May 2;256(3):281-6.

U-50,488, (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]- benzeneacetamide hydrochloride), is a selective kappa-opioid receptor agonist. In this study, we found that U-50,488 antagonized morphine-induced antinociception in morphine-naive guinea pigs at doses which did not have any antinociceptive effect by themselves (0.01-3 mg/kg). On the other hand, U-50,488 (3 mg/kg) partially restored morphine-induced antinociception in morphine-tolerant guinea pigs (8 mg/kg/day i.p. morphine HCl for 6 days). Furthermore, the development of tolerance to morphine antinociception was completely blocked by coadministration of U-50,488 at a very low dose (0.003 mg/kg i.p.) which neither exerted an antinociceptive effect by itself nor affected the antinociception induced by 8 mg/kg of morphine HCl. The withdrawal signs induced by 8 mg/kg (i.p.) naloxone HCl on the 7th day were also depressed by coadministration of 0.003 mg/kg U-50,488 with morphine HCl (8 mg/kg i.p.) every day for 7 days. These effects of U-50,488 could be applied to humans to prevent morphine tolerance and dependence.

Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices.[Pubmed:7679733]

J Pharmacol Exp Ther. 1993 Feb;264(2):648-53.

The modulation of the release of substance P (SP) from sensory primary afferents by activation of kappa opioid receptors is not only equivocal, but also contradictory. Thus, in the present study, we have determined the effect of nanomolar concentrations of the highly selective kappa opioid receptor agonist trans-(+)-3,4-dichloro-N-methyl-N-[2-91- (pyrrolidinyl)cyclohexyl]benzacetamide methane sulphonate (U50488H), as well as micromolar concentrations of moderately mu-selective agonist morphine, on K(+)-evoked SP release from rat trigeminal nucleus caudalis slices. U50488H (10-30 nM) and morphine (10-30 microM) increased K(+)-evoked SP release without stimulating basal SP release. Both U50488H and morphine concentration-response curves were biphasic because the highest and the lowest concentrations of U50488H (100 nM) and morphine (3 microM) tested, respectively, inhibited SP release. Enhancement of K(+)-evoked SP release induced by 30 nM U50488H and 30 microM morphine was blocked by the opioid receptor antagonists naloxone (30 nM; nontype selective) and norbinaltorphimine (3 nM; kappa selective), but not by N,N diallyl Tyr-Aib-Aib-Phe-Leu (0.3 microM; delta selective), naloxonazine (1 nM; mu 1 selective) or beta-funaltrexamine (20 nM; mu selective). These findings indicate that activation of at least one population of kappa opioid receptors increases the release of SP from trigeminal nucleus caudalis. Excitatory presynaptic kappa opioid receptors on SP-containing primary afferents may be involved in the hyperalgesia of inflammatory processes, the "anti-analgesic" effect of dynorphin and the paradoxical "analgesia" produced by low doses of naloxone.

Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.[Pubmed:1320979]

Br J Pharmacol. 1992 Mar;105(3):521-6.

1. The cardiovascular actions of U-50,488H, a kappa-receptor agonist, were studied in rat isolated perfused hearts, and in anaesthetized rats, over concentrations or doses generally above those required to produce kappa-receptor-mediated effects. 2. U-50,488H dose-dependently decreased left-ventricular peak systolic pressure and beating rate in vitro and reduced blood pressure and heart rate in vivo. 3. Over the concentration range of 1-30 microM in vitro, and the dose-range of 0.5-32 mumol kg-1 in vivo, U-50,488H prolonged the P-R, QRS and Q-T intervals of the ECG. 4. The effects of U-50,488H were not antagonized by an opioid receptor antagonist, naloxone (1 microM or 8 mumol kg-1). Similarly, the opioid receptor antagonist, MR 2266, at 8 mumol kg-1 did not significantly reduce the cardiovascular actions of U-50,488H in vivo. 5. The actions of U-50,488H on responses to electrical stimulation were also studied. Over the dose range of 0.5-32 mumol kg-1, U-50,488H altered thresholds and effective refractory period. It had a biphasic action on thresholds for induction of ventricular fibrillation. Thresholds were decreased at lower doses (0.5-4 mumol kg-1) but increased at higher doses (8-32 mumol kg-1). The effects of lower doses were blocked by naloxone. Effective refractory period and threshold pulse width only increased with dose. 6. In conclusion, U-50,488H at high concentration, had direct depressant actions on cardiac contractility, electrical excitability and the ECG. These depressant effects were not antagonized by the opioid receptor antagonists, naloxone and MR 2266, and probably do not involve opioid receptors. Furthermore, some of the observed effects were those expected to result from sodium channel blockade.

Keywords:

(±)-U-50488 hydrochloride,67197-96-0,Natural Products,Opioid Receptor, buy (±)-U-50488 hydrochloride , (±)-U-50488 hydrochloride supplier , purchase (±)-U-50488 hydrochloride , (±)-U-50488 hydrochloride cost , (±)-U-50488 hydrochloride manufacturer , order (±)-U-50488 hydrochloride , high purity (±)-U-50488 hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: